Immunogenicity Assessment of the SARS-CoV-2 Protein Subunit Recombinant Vaccine (CoV2-IB 0322) in a Substudy of a Phase 3 Trial in Indonesia.
Sharifah ShakinahMuhammad Hafiz AiniRini Sekartininull SoedjatmikoBernie Endyarni MediseHartono GunardiIrene YuniarWahyuni IndawatiSukamto KoesnoeKuntjoro HarimurtiSuzy MariaAngga WirahmadiRini Mulia SariLilis SetyaningsihFikrianti SurachmanPublished in: Vaccines (2024)
Both vaccines showed comparable B- and T-cell immunological response that diminish over time.